Gallstones: Cholestatic Signals When Bile Flow Is Blocked

REVIEWED BY

William Maish, MD MBA MPH

Clinical Product Lead

Published

Last updated

Key takeaway:

Blood testing for gallstones uses ALP, GGT, and direct bilirubin to detect early signs of bile-duct obstruction caused by stones. When a stone blocks the duct, ALP and GGT rise (normally ~40–120 and ~10–71 respectively) and direct bilirubin climbs above 0.3 mg/dL, often with right-upper-quadrant pain and jaundice, guiding urgency for imaging and endoscopic intervention.

Read more →

Understand what your liver function testing results really mean

See your biomarkers in context with a comprehensive panel.

  • CLIA-certified labs
  • HIPAA compliant
  • Personalized health protocol
Book your test

Gallstones and the cholestatic signals they leave

Gallstone biomarkers are blood signals that tell how stones in the gallbladder or bile ducts are affecting bile flow, the liver, and nearby organs. They don’t detect a stone directly; they reveal the body’s reaction to blockage or irritation. Key markers of bile flow problems (cholestasis) include bilirubin (a bile pigment), alkaline phosphatase and gamma‑glutamyl transferase (enzymes made by bile‑duct lining). Markers of liver cell stress include ALT and AST (hepatocellular enzymes). If a stone lodges near the pancreas, pancreatic enzymes such as amylase and lipase reflect pancreatic involvement (gallstone pancreatitis). When there is inflammation or infection, general signals like white blood cell count and C‑reactive protein indicate systemic response. Together, these biomarkers help clinicians judge urgency, choose the right imaging, and track recovery after the obstruction resolves. In short, gallstone biomarkers translate the hidden traffic of bile into measurable clues about obstruction, inflammation, and organ stress, so care can be directed quickly and appropriately.

Join 150,000+ others building better health

Get the science behind better health, every week.

By clicking “Subscribe” you agree to our Terms of Service and Privacy Policy.

Why a bile-flow panel matters

Blood tests for gallstones look at cholestatic biomarkers—alkaline phosphatase (ALP), gamma‑glutamyl transferase (GGT), and direct (conjugated) bilirubin—that reveal how well bile moves from liver to intestine. When a stone blocks the bile duct, pressure builds, bile backs up into blood, and these markers change well before complications spread to the liver, pancreas, gut, and skin. Typical adult reference ranges are: ALP roughly 40–120, GGT around 10–71 in men and 6–42 in women, and direct bilirubin about 0.0–0.3. In health, ALP sits mid‑range, GGT toward the lower end, and direct bilirubin near zero. With a duct blocked by a stone, ALP and GGT rise as the biliary epithelium reacts to stasis, and direct bilirubin climbs as conjugated pigment regurgitates into blood—often accompanied by right‑upper‑quadrant pain, dark urine, pale stools, itching, and jaundice. Marked elevations point to higher obstruction risk and, if severe, can spill over into pancreatitis or cholangitis. Lower readings tell a different story. A low GGT is common in pregnancy and younger adults and does not suggest stones. Low ALP can reflect non‑biliary issues (e.g., low bone turnover states); it does not produce biliary symptoms or indicate obstruction. Direct bilirubin near zero signals unobstructed bile flow. Age and sex matter: adolescents often have higher ALP from bone growth; pregnancy raises ALP via placental isoenzymes while GGT tends to drop; women generally have lower GGT than men. Big picture, these markers sit at the crossroads of liver, biliary tree, pancreas, and intestine. Their pattern, alongside symptoms, helps identify choledocholithiasis early, gauge severity, and anticipate risks like infection, pancreatitis, and liver injury, especially when integrated with AST/ALT, lipase, and imaging.

Test 100+ biomarkers from home

One blood draw. A full picture of your health, explained in plain language.

Book your test

What bloodwork reveals about stones — and what imaging has to confirm

Gallstones blood testing provides insight into how well your liver and biliary system are functioning—key players in digestion, energy metabolism, and the body’s ability to clear waste. When gallstones disrupt the normal flow of bile, this can affect not only digestion but also broader systems like cardiovascular health, immunity, and even hormone balance. At Superpower, we assess three main biomarkers for gallstones: alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), and direct (conjugated) bilirubin. ALP is an enzyme found in the cells lining the bile ducts. When gallstones block these ducts, ALP levels often rise, signaling stress or injury in the biliary system. GGT is another enzyme concentrated in the liver and bile ducts; it tends to increase when there is bile flow obstruction or liver cell irritation. Direct bilirubin measures the form of bilirubin that has been processed by the liver and is ready to be excreted in bile. Elevated direct bilirubin suggests that bile is not flowing freely, often due to blockage from gallstones. Stable, healthy levels of ALP, GGT, and direct bilirubin indicate that bile is moving smoothly from the liver through the bile ducts into the intestine. This supports efficient digestion, waste removal, and metabolic balance. Disruptions in these markers can signal early or ongoing issues with gallstone formation or movement, even before symptoms appear. Interpretation of these biomarkers can be influenced by factors such as age, pregnancy, recent illness, certain medications, and individual lab methods. These variables are important to consider when understanding your results.

Frequently Asked Questions

References

  1. Lammert F, Gurusamy K, Ko CW, Miquel JF, Méndez-Sánchez N, Portincasa P, van Erpecum KJ, van Laarhoven CJ, Wang DQ (2016). Gallstones. *Nature Reviews Disease Primers*, *2*, 16024. https://doi.org/10.1038/nrdp.2016.24
  2. Tenner S, Baillie J, DeWitt J, Vege SS (2013). American College of Gastroenterology guideline: Management of acute pancreatitis. *The American Journal of Gastroenterology*, *108*(9), 1400-1415. https://doi.org/10.1038/ajg.2013.218
  3. European Association for the Study of the Liver. (2016). EASL clinical practice guidelines on the prevention, diagnosis and treatment of gallstones. *Journal of Hepatology*, *65*(1), 146-181. https://doi.org/10.1016/j.jhep.2016.03.005
  4. National Institute of Diabetes and Digestive and Kidney Diseases. (2017). *Gallstones*. https://www.niddk.nih.gov/health-information/digestive-diseases/gallstones
  5. Mayo Clinic. (n.d.). *Gallstones: Symptoms and causes*. https://www.mayoclinic.org/diseases-conditions/gallstones/symptoms-causes/syc-20354214

Led by doctors with 40 years of health and longevity expertise

Dr. Anant Vinjamoori

Dr. Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Dr. Leigh Erin Connealy

Dr. Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Dr. Robert Lufkin

Dr. Robert Lufkin, MD

Physician & UCLA Medical School Professor, NYT bestselling author

Dr. Abe Malkin

Dr. Abe Malkin, MD

Founder & Medical Director of Concierge MD

Membership 1
1 / 4

Your membership starts here

Annual 100+ biomarker panel

  • Data dashboard and digital twin
  • Upload past labs and connect wearables
  • Personalized health protocol
  • 24/7 care team access
  • AI companion for all health questions
  • Marketplace with additional solutions
$199
/year*Billed annually
Get started
HSA/FSA eligibleCancel anytimeResults in a week

*Pricing may vary for members in New York and New Jersey